Disease response by Ven duration and for all patients
| Response . | 8-day Ven (n = 14), n (%) . | 11-day Ven (n = 9), n (%) . | 14-day Ven (n = 11), n (%) . | All Cohorts (N = 34), n (%) . |
|---|---|---|---|---|
| No response | 3 (21) | 1 (11) | 1 (9) | 5 (15) |
| CR | 10 (71) | 8 (89) | 10 (91) | 28 (82) |
| CRh | 1 (7) | — | — | 1 (3) |
| CRcMRD– | 9/11 (82) | 7/8 (87.5) | 9/10 (90) | 25/29 (86) |
| Allogeneic transplant in CR1 | 3 (22) | 3 (33) | 4 (36) | 10 (29) |
| Response . | 8-day Ven (n = 14), n (%) . | 11-day Ven (n = 9), n (%) . | 14-day Ven (n = 11), n (%) . | All Cohorts (N = 34), n (%) . |
|---|---|---|---|---|
| No response | 3 (21) | 1 (11) | 1 (9) | 5 (15) |
| CR | 10 (71) | 8 (89) | 10 (91) | 28 (82) |
| CRh | 1 (7) | — | — | 1 (3) |
| CRcMRD– | 9/11 (82) | 7/8 (87.5) | 9/10 (90) | 25/29 (86) |
| Allogeneic transplant in CR1 | 3 (22) | 3 (33) | 4 (36) | 10 (29) |
CR, complete remission; CRh, complete remission with partial hematologic recovery; CRcMRD–, measurable residual disease–negative composite CR by multiparameter flow cytometry (Hematologics Inc); CR1, first complete remission.